Toll-like receptors and NOD-like receptors in rheumatic diseases.

Hdl Handle:
http://hdl.handle.net/10147/207807
Title:
Toll-like receptors and NOD-like receptors in rheumatic diseases.
Authors:
McCormack, William J; Parker, Andrew E; O'Neill, Luke A
Affiliation:
OPSONA Therapeutics Ltd, Institute of Molecular Medicine, Trinity Centre for, Health Sciences, St James' Hospital, Dublin 8, Ireland. wmccormack@opsona.com
Citation:
Arthritis Res Ther. 2009;11(5):243. Epub 2009 Oct 14.
Journal:
Arthritis research & therapy
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207807
DOI:
10.1186/ar2729
PubMed ID:
19835640
Abstract:
The past 10 years have seen the description of families of receptors that drive proinflammatory cytokine production in infection and tissue injury. Two major classes have been examined in the context of inflammatory joint disease--the Toll-like receptors (TLRs) and NOD-like receptors (NLRs). TLRs such as TLR2 and TLR4 are being implicated in the pathology of rheumatoid arthritis, ankylosing spondylitis, lyme arthritis and osteoarthritis. Nalp3 has been identified as a key NLR for IL-1beta production and has been shown to have a particular role in gout. These findings present new therapeutic opportunities, possibly allowing for the replacement of biologics with small molecule inhibitors.
Language:
eng
MeSH:
Animals; Humans; Nod Signaling Adaptor Proteins/immunology/*metabolism; Rheumatic Diseases/immunology/*metabolism; Toll-Like Receptors/immunology/*metabolism
ISSN:
1478-6362 (Electronic); 1478-6354 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorMcCormack, William Jen_GB
dc.contributor.authorParker, Andrew Een_GB
dc.contributor.authorO'Neill, Luke Aen_GB
dc.date.accessioned2012-02-01T10:45:16Z-
dc.date.available2012-02-01T10:45:16Z-
dc.date.issued2012-02-01T10:45:16Z-
dc.identifier.citationArthritis Res Ther. 2009;11(5):243. Epub 2009 Oct 14.en_GB
dc.identifier.issn1478-6362 (Electronic)en_GB
dc.identifier.issn1478-6354 (Linking)en_GB
dc.identifier.pmid19835640en_GB
dc.identifier.doi10.1186/ar2729en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207807-
dc.description.abstractThe past 10 years have seen the description of families of receptors that drive proinflammatory cytokine production in infection and tissue injury. Two major classes have been examined in the context of inflammatory joint disease--the Toll-like receptors (TLRs) and NOD-like receptors (NLRs). TLRs such as TLR2 and TLR4 are being implicated in the pathology of rheumatoid arthritis, ankylosing spondylitis, lyme arthritis and osteoarthritis. Nalp3 has been identified as a key NLR for IL-1beta production and has been shown to have a particular role in gout. These findings present new therapeutic opportunities, possibly allowing for the replacement of biologics with small molecule inhibitors.en_GB
dc.language.isoengen_GB
dc.subject.meshAnimalsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshNod Signaling Adaptor Proteins/immunology/*metabolismen_GB
dc.subject.meshRheumatic Diseases/immunology/*metabolismen_GB
dc.subject.meshToll-Like Receptors/immunology/*metabolismen_GB
dc.titleToll-like receptors and NOD-like receptors in rheumatic diseases.en_GB
dc.contributor.departmentOPSONA Therapeutics Ltd, Institute of Molecular Medicine, Trinity Centre for, Health Sciences, St James' Hospital, Dublin 8, Ireland. wmccormack@opsona.comen_GB
dc.identifier.journalArthritis research & therapyen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.